Table 4.
Serious adverse effects
| Event | MSC group (N = 99) | Control group (N = 99) |
|---|---|---|
| Any adverse event | 41 (41.4%) | 44 (44.4%) |
| Hematologica | 9 (9.1%) | 13 (13.1%) |
| Platelets decreased | 6 (6.1%) | 8 (8.1%) |
| Platelet and neutrophil both decreased | 3 (3.0%) | 5 (5.1%) |
| Skinb | 0 (0%) | 1 (1.0%) |
| Gastrointestinalb | 4 (4.0%) | 5 (5.1%) |
| Hepatobilinary or pancreaticb | 2 (2.0%) | 2 (2.0%) |
| Cardiac (heart failure) | 4 (4.0%) | 6 (6.1%) |
| Renal or genitourinary (cystitis non-infective) | 4 (4.0%) | 5 (5.1%) |
| Vascular (thrombotic microangiopathy) | 0 (0%) | 1 (1.0%) |
| Infections | 12 (12.1%) | 16 (16.2%) |
| Secondary malignant disease | 0 (0%) | 0 (0%) |
aIncluded patients with decreases in platelet counts and neutrophil counts
bExcluded patients with aGVHD